Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BGB324 in combination with pembrolizumab in previously treated triple negative breast cancer
2016-003608-30Phase 2Completed
- Sponsor
- BerGenBio ASA
- Start
- Mar 2017
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bemcentinib and pembrolizumab in triple-negative breast cancer (TNBC) and inflammatory breast cancer (IBC), sponsored by BerGenBio ASA. Primary endpoint: Objective Response Rate. Started Mar 2017; status: completed.
02
Drugs
bemcentinibpembrolizumab
03
Conditions
triple-negative breast cancer (TNBC)inflammatory breast cancer (IBC)
Beyond the preview
Go deeper on 2016-003608-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003608-30.